XNAS
SHC
Market cap5.10bUSD
Oct 07, Last price
17.90USD
1D
-1.92%
1Q
-2.66%
IPO
-35.96%
Name
Sotera Health Co
Chart & performance
P/E
65.48
P/S
4.39
EPS
0.27
Div yield, %
—
Shrs. gr., 5y
0.22%
Rev. gr., 5y
7.30%
Revenues
1.16b
+5.74%
Net income
78m
+75.57%
CFO
287m
+28.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Sotera Health Company, headquartered in Broadview Heights, Ohio, delivers essential sterilization, laboratory testing, and advisory services to a global clientele spanning North America, Europe, and various international regions. The firm's sterilization capabilities encompass gamma and electron beam irradiation, alongside ethylene oxide (EO) processing. Through its Nelson Labs division, Sotera Health conducts comprehensive microbiological and analytical chemistry analyses. Additionally, it offers specialized consulting to the medical device and biopharmaceutical industries. Sotera Health serves a diverse array of sectors, including medical device manufacturers, pharmaceutical companies, producers of food and agricultural products, and various commercial, advanced, and specialty application industries. Incorporated in 2017, the company was previously known as Sotera Health Topco, Inc., adopting its current name in October 2020.
Key people
Michael Rutz
President of Sterigenics · since 2020
Jonathan Lyons
Chief Financial Officer, Senior Vice President · since 2023
Senior Vice President, General Counsel · since 2024
Michael Petras
Chairman of the Board, Chief Executive Officer · since 2020
Ruoxi Chen
Independent Director · since 2020
Independent Director · since 2020
Independent Director · since 2023
Independent Director · since 2020
Robert Knauss
Independent Director · since 2022
Independent Director · since 2020
Lead Independent Director · since 2025
Independent Director · since 2024
David Wheadon
Independent Director · since 2021
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||